Phase 1 EGFR Gene Mutation Clinical Trials

3 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–3 of 3 trials

Recruiting

Phase 1

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more

Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401

Recruiting

Phase 1Phase 2

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Gene Mutation

China Medical University Hospital20 enrolled1 locationNCT06071013

Recruiting

Phase 1

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Lung Cancer MetastaticEGFR Gene Mutation

Collin Blakely38 enrolled1 locationNCT04085315